[ad_1]
Advance purchase of 700 million batches in each country during the start of phase 3 by pharmaceutical companies
Vaccine prevention rate in the range of 94-95% … Countries, from approval to vaccination, ‘ultra-fast’
Additional research is needed, such as safety and effects on mutant viruses.
End Corona 19 and daily recovery over the next year, some countries are concerned
[앵커]
Since the early days of the Corona 19 outbreak, countries have focused on development, as vaccines and treatments are the only means to counter the virus. As a result, this year’s development began until vaccination, but anxiety that safety has not been sufficiently verified has become a reality and vaccine selfishness among countries is growing. Reporter Kim Jeong-hoe summarized the vaccine development process and current direction, which we reviewed in the first year of the COVID-19 outbreak. The United States was the first to develop a vaccine. One month after a new infectious disease with ‘Wuhan Population Pneumonia’ was reported to WHO, we declared the development of a new mRNA-based vaccine. Spring in the gloomy global village. However, the competition for vaccine development ignited with the successive additions of global pharmaceutical companies. Clinical trials are also accelerating. News of the competition for supplies from each country is delivered amid the successive launch of the three phases of the pharmaceutical companies. Before the official launch of the vaccine, huge subsidies were invested to pharmaceutical companies from the beginning of development and focused on individual negotiations. It turns out that high-income countries have consumed 700 million servings. Pfizer 95%, Modena 94.1%. The world applauded the effect beyond expectations. An important milestone has been set to end Corona 19, and from approval of emergency use to vaccination, it has been processed at high speed. Chinese vaccines have also begun signing a full contract with a three-phase overseas vaccine, and AstraZeneca, Johnson & Johnson-Jansen are also preparing for approval from each country. But you can’t just be happy. The issue of safety remains controversial, and more research is needed to see if approved vaccines work against the reported mutant virus in countries starting in the UK and South Africa. Excluding some of the treatments, clinical trials have been discontinued or are at an early clinical stage, so their use on a large scale is not possible. More importantly, due to the sweep of some countries, many countries will have a difficult time getting vaccinated next year. Even countries with stable quarantine conditions have secured a large number of vaccines. It is more likely that it will be up to some countries to end Corona 19 and return to everyday life. This is YTN Kim Jeong-hoe.
